BioXcel Therapeutics (BTAI) Competitors $1.39 -0.03 (-2.11%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. BLUE, KZR, FGEN, MRNS, INKT, ALLK, SCLX, CALC, GRCE, and SRZNShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include bluebird bio (BLUE), Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Scilex (SCLX), CalciMedica (CALC), Grace Therapeutics (GRCE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. bluebird bio Kezar Life Sciences FibroGen Marinus Pharmaceuticals MiNK Therapeutics Allakos Scilex CalciMedica Grace Therapeutics Surrozen BioXcel Therapeutics (NASDAQ:BTAI) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Is BTAI or BLUE more profitable? bluebird bio has a net margin of -565.74% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% bluebird bio -565.74%-322.46%-53.17% Do insiders and institutionals have more ownership in BTAI or BLUE? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by insiders. Comparatively, 1.4% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in BTAI or BLUE? bluebird bio received 794 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 70.34% of users gave bluebird bio an outperform vote while only 67.67% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24767.67% Underperform Votes11832.33% bluebird bioOutperform Votes104170.34% Underperform Votes43929.66% Which has preferable earnings & valuation, BTAI or BLUE? BioXcel Therapeutics has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$1.85M4.55-$179.05M-$13.55-0.10bluebird bio$83.81M0.58-$211.91M-$41.32-0.12 Does the media prefer BTAI or BLUE? In the previous week, bluebird bio had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 5 mentions for bluebird bio and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.30 beat bluebird bio's score of -0.06 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral bluebird bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer BTAI or BLUE? BioXcel Therapeutics presently has a consensus price target of $42.60, suggesting a potential upside of 2,964.75%. bluebird bio has a consensus price target of $44.60, suggesting a potential upside of 796.48%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than bluebird bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility & risk, BTAI or BLUE? BioXcel Therapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. SummaryBioXcel Therapeutics beats bluebird bio on 11 of the 19 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.42M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.048.9726.6219.77Price / Sales4.55253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book-0.056.486.814.53Net Income-$179.05M$143.98M$3.23B$248.18M7 Day Performance1.46%3.37%4.05%1.06%1 Month Performance-18.71%7.83%11.64%14.68%1 Year Performance-95.68%-2.24%17.11%6.87% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics3.95 of 5 stars$1.39-2.1%$42.60+2,964.7%-95.8%$8.42M$1.85M-0.0490BLUEbluebird bio2.7176 of 5 stars$3.29-6.0%$44.60+1,255.6%-75.8%$32.21M$83.81M-0.09520High Trading VolumeKZRKezar Life Sciences4.2212 of 5 stars$4.23+0.2%$39.50+833.8%-46.6%$30.90M$7M-0.3260Positive NewsFGENFibroGen4.4121 of 5 stars$0.31-0.8%$10.00+3,174.4%-71.3%$30.86M$29.62M-0.25570MRNSMarinus Pharmaceuticals1.8985 of 5 stars$0.55-0.2%$4.79+771.6%-59.3%$30.32M$30.99M-0.22110News CoverageAnalyst ForecastINKTMiNK Therapeutics2.6544 of 5 stars$7.60+8.1%$37.50+393.4%-26.1%$30.14MN/A-1.9530Earnings ReportAnalyst RevisionGap UpALLKAllakos4.2686 of 5 stars$0.33+0.3%$2.00+506.8%N/A$29.79MN/A-0.16190SCLXScilex1.5518 of 5 stars$4.10+2.2%$455.00+10,997.6%-88.2%$28.50M$56.59M-4.9480High Trading VolumeCALCCalciMedica2.5882 of 5 stars$2.01+0.5%$18.00+795.5%-65.3%$28.08MN/A-1.8630Earnings ReportGRCEGrace Therapeutics1.896 of 5 stars$2.72flat$12.00+341.2%N/A$27.58MN/A-2.34N/ASRZNSurrozen3.0023 of 5 stars$8.00-4.2%$38.50+381.3%-10.5%$26.25M$10.66M-0.3280Gap Down Related Companies and Tools Related Companies bluebird bio Alternatives Kezar Life Sciences Alternatives FibroGen Alternatives Marinus Pharmaceuticals Alternatives MiNK Therapeutics Alternatives Allakos Alternatives Scilex Alternatives CalciMedica Alternatives Grace Therapeutics Alternatives Surrozen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTAI Stock Free BTAI Stock Alerts